Insmed Incorporated (ETR:IM8N)

Market Cap	21.83B -27.2%
Revenue (ttm)	1.34B +240.0%
Net Income	-533.30M
EPS	-2.50
Shares Out	n/a
PE Ratio	n/a
Forward PE	9,106.57
Dividend	n/a
Ex-Dividend Date	n/a

Volume	364
Open	88.38
Previous Close	86.82
Day's Range	88.38 - 103.50
52-Week Range	83.00 - 118.08
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 29, 2026

About Insmed

Insmed Incorporated develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of refractory nontuberculous mycobacterial lung infections, as well as is in phase 3 clinical trial for the treatment of mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It also develops brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1(DPP1) that is in phase 3 ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1988
• Employees: 1,664
• Stock Exchange: Deutsche Börse Xetra
• Ticker Symbol: IM8N

Financial Performance

In 2025, Insmed's revenue was $606.42 million, an increase of 66.73% compared to the previous year's $363.71 million. Losses were -$1.28 billion, 39.7% more than in 2024.

Financial numbers in USD

Data Sources: S&P Global Market Intelligence and Twelve Data

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Twelve Data.

Last checked:

Oct 30, 2026

Data Sources Report a data error